UY36705A - Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj - Google Patents

Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj

Info

Publication number
UY36705A
UY36705A UY0001036705A UY36705A UY36705A UY 36705 A UY36705 A UY 36705A UY 0001036705 A UY0001036705 A UY 0001036705A UY 36705 A UY36705 A UY 36705A UY 36705 A UY36705 A UY 36705A
Authority
UY
Uruguay
Prior art keywords
heteroaril
piridin
hydroxi
compounds
apj agonists
Prior art date
Application number
UY0001036705A
Other languages
English (en)
Inventor
James A Johnson
Soong-Hoon Kim
R Michael Lawrence
Michael C Myers
Hannguang J Chao
Phillips Monique
Jiang Ji
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY36705A publication Critical patent/UY36705A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

La presente invención proporciona compuestos de la Fórmula (I):en donde todas las variables son como se definen en la memoria descriptiva, y composiciones que comprenden cualquiera de tales compuestos novedosos. Estos compuestos son agonistas de APJ, que se pueden usar como medicamentos.
UY0001036705A 2015-06-03 2016-06-02 Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj UY36705A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562170215P 2015-06-03 2015-06-03

Publications (1)

Publication Number Publication Date
UY36705A true UY36705A (es) 2016-11-30

Family

ID=56131647

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036705A UY36705A (es) 2015-06-03 2016-06-02 Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj

Country Status (35)

Country Link
US (3) US10011594B2 (es)
EP (2) EP3303330B1 (es)
JP (2) JP6483288B2 (es)
KR (1) KR102066336B1 (es)
CN (1) CN107922401B (es)
AR (1) AR104884A1 (es)
AU (1) AU2016270903B2 (es)
CA (1) CA2988147C (es)
CL (1) CL2017003055A1 (es)
CO (1) CO2017013229A2 (es)
CY (1) CY1121938T1 (es)
DK (1) DK3303330T3 (es)
EA (1) EA034912B1 (es)
ES (1) ES2739526T3 (es)
HK (1) HK1247915B (es)
HR (1) HRP20191327T1 (es)
HU (1) HUE045546T2 (es)
IL (1) IL255951B (es)
LT (1) LT3303330T (es)
MA (1) MA41562B1 (es)
ME (1) ME03474B (es)
MX (1) MX2017014956A (es)
MY (1) MY189453A (es)
NZ (1) NZ738563A (es)
PE (1) PE20180506A1 (es)
PH (1) PH12017502158A1 (es)
PL (1) PL3303330T3 (es)
PT (1) PT3303330T (es)
RS (1) RS59220B1 (es)
SI (1) SI3303330T1 (es)
TN (1) TN2017000503A1 (es)
TW (1) TWI672299B (es)
UY (1) UY36705A (es)
WO (1) WO2016196771A1 (es)
ZA (1) ZA201708191B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
NZ738563A (en) 2015-06-03 2019-09-27 Bristol Myers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
UY36949A (es) 2015-10-14 2017-04-28 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware 2,4-dihidroxi-nicotinamidas como agonistas de apj
PE20181269A1 (es) 2015-12-04 2018-08-03 Bristol Myers Squibb Co Agonistas del receptor de apelina y metodos de uso
CN108602813B (zh) * 2015-12-16 2021-10-29 百时美施贵宝公司 作为apj受体激动剂的杂芳基羟基嘧啶酮
JP6716711B2 (ja) * 2016-03-24 2020-07-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊアゴニストとしての６−ヒドロキシ−４−オキソ−１，４−ジヒドロピリミジン−５−カルボキシアミド
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2017218633A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
ES2844184T3 (es) * 2016-06-14 2021-07-21 Bristol Myers Squibb Co 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
KR102521956B1 (ko) * 2016-10-14 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
CN109734616B (zh) * 2019-02-16 2022-05-13 安徽诺全药业有限公司 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
CN109704981B (zh) * 2019-02-16 2022-01-28 安徽诺全药业有限公司 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001159A (en) 1910-07-25 1911-08-22 Elizabeth Nielsen Skirt-gage.
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US4866182A (en) 1988-02-18 1989-09-12 Merrell Dow Pharmaceuticals Inc. Cardiotonic alkanoyl and aroyl oxazolones
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
RU2319701C2 (ru) 2001-02-21 2008-03-20 Астразенека Аб ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I
EA006154B1 (ru) 2001-03-28 2005-10-27 Пфайзер Инк. N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad
US7399759B2 (en) 2001-09-03 2008-07-15 Takeda Pharmaceutical Company Limited 1, 3-benzothiazinone derivatives and use thereof
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
GEP20063937B (en) * 2002-02-14 2006-10-10 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
US20060004001A1 (en) 2004-02-27 2006-01-05 Merz Pharma Gmbh & Co., Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
ATE454372T1 (de) 2004-04-01 2010-01-15 Lilly Co Eli Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
WO2006002099A2 (en) 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
ATE432926T1 (de) 2004-07-26 2009-06-15 Lilly Co Eli Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP2049497A2 (en) * 2005-05-19 2009-04-22 Astex Therapeutics Limited Pyrimidine derivatives as hsp90 inhibitors
WO2007023242A1 (en) 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
GEP20125643B (en) 2006-01-23 2012-09-25 Amgen Inc Aurora kinase modulators and method of using same
JP2007314516A (ja) 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd ２以上の置換基を有するベンゼン化合物を含有する医薬
JP5270545B2 (ja) 2006-08-03 2013-08-21 タフツ ユニバーシティー／トラスティーズ オブ タフツ カレッジ フラッシングのないナイアシン類似体およびそれらの使用法
EP2099768A2 (en) 2006-08-04 2009-09-16 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine-1-phosphate receptor
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
US20100035860A1 (en) 2006-12-01 2010-02-11 Jey Raju Jeyaseelan Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
EP2142546B1 (en) 2007-03-28 2017-06-07 Saniona A/S Purinyl derivatives and their use as potassium channel modulators
EP2674417A3 (en) * 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl PDE4 inhibitors for treating inflammation
WO2009093264A2 (en) 2008-01-25 2009-07-30 Torrent Pharmaceuticals Ltd. Pharmaceutical combinations
AR072249A1 (es) 2008-04-09 2010-08-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso. usos. metodos.
AU2009253046A1 (en) 2008-05-30 2009-12-03 Foster Wheeler Energia Oy Method of and system for generating power by oxyfuel combustion
CN102137866A (zh) 2008-06-30 2011-07-27 赛林药物股份有限公司 羟吲哚化合物
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
CN103396474A (zh) * 2008-11-04 2013-11-20 安科治疗公司 Apj受体化合物
WO2011036130A1 (en) 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators
MX2012002958A (es) 2009-09-24 2012-04-19 Hoffmann La Roche Compuestos antivirales heterociclicos.
WO2011062955A2 (en) 2009-11-18 2011-05-26 University Of Massachusetts Compounds for modulating tlr2
EA201200917A1 (ru) 2009-12-18 2012-12-28 Эктивсайт Фармасьютикалз, Инк. Пролекарства ингибиторов плазменного калликреина
CN102241621A (zh) 2010-05-11 2011-11-16 江苏恒瑞医药股份有限公司 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用
US9096531B2 (en) 2010-05-24 2015-08-04 Toa Eiyo Ltd. Fused imidazole derivative
JP5869579B2 (ja) * 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
WO2012074022A1 (ja) 2010-12-01 2012-06-07 旭硝子株式会社 イリジウムカチオン錯体および発光組成物
US20140057953A1 (en) 2011-03-03 2014-02-27 Rolf Hartmann Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
US8691861B2 (en) 2011-04-13 2014-04-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
KR20140115329A (ko) 2011-12-23 2014-09-30 바스프 에스이 무척추동물 해충 퇴치를 위한 이소티아졸린 화합물
WO2013164769A1 (en) * 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
WO2013167633A1 (en) 2012-05-09 2013-11-14 Basf Se Acrylamide compounds for combating invertebrate pests
PT2858975T (pt) 2012-06-08 2019-07-16 Univ Pittsburgh Commonwealth Sys Higher Education Inibidores de fbxo3
US20160008339A1 (en) 2012-07-02 2016-01-14 Max-Delbruck-Centrum Fur Molekulare Medizin Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
CN104640846A (zh) * 2012-09-21 2015-05-20 赛诺菲 用作apj受体调节剂的苯并咪唑-羧酸酰胺衍生物
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP6199197B2 (ja) 2014-02-07 2017-09-20 花王株式会社 ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法
JP2017071553A (ja) 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
US20170107212A1 (en) 2014-03-20 2017-04-20 Bayer Pharma Aktiengesellschaft Novel compounds
JP6552061B2 (ja) 2014-06-10 2019-07-31 サンフォード−バーンハム メディカル リサーチ インスティテュート 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
NZ738563A (en) 2015-06-03 2019-09-27 Bristol Myers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
UY36949A (es) 2015-10-14 2017-04-28 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware 2,4-dihidroxi-nicotinamidas como agonistas de apj
US10626096B2 (en) 2015-11-24 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Azole derivatives as apelin receptor agonist
PE20181269A1 (es) 2015-12-04 2018-08-03 Bristol Myers Squibb Co Agonistas del receptor de apelina y metodos de uso
US10100059B2 (en) 2015-12-09 2018-10-16 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
CN108602813B (zh) 2015-12-16 2021-10-29 百时美施贵宝公司 作为apj受体激动剂的杂芳基羟基嘧啶酮
JP6716711B2 (ja) 2016-03-24 2020-07-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊアゴニストとしての６−ヒドロキシ−４−オキソ−１，４−ジヒドロピリミジン−５−カルボキシアミド
ES2844184T3 (es) 2016-06-14 2021-07-21 Bristol Myers Squibb Co 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
WO2017218633A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
KR102521956B1 (ko) 2016-10-14 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제

Also Published As

Publication number Publication date
NZ738563A (en) 2019-09-27
DK3303330T3 (da) 2019-08-05
KR102066336B1 (ko) 2020-01-14
MX2017014956A (es) 2018-04-13
IL255951B (en) 2021-06-30
HRP20191327T1 (hr) 2019-11-01
US20180273518A1 (en) 2018-09-27
HUE045546T2 (hu) 2020-01-28
MA41562A1 (fr) 2018-05-31
CA2988147A1 (en) 2016-12-08
ZA201708191B (en) 2019-07-31
PT3303330T (pt) 2019-08-05
PL3303330T3 (pl) 2019-10-31
CL2017003055A1 (es) 2018-05-25
TW201708214A (zh) 2017-03-01
TWI672299B (zh) 2019-09-21
AU2016270903B2 (en) 2020-04-30
AU2016270903A1 (en) 2018-01-18
EP3303330A1 (en) 2018-04-11
CN107922401B (zh) 2021-04-16
SI3303330T1 (sl) 2019-08-30
LT3303330T (lt) 2019-08-12
EA034912B1 (ru) 2020-04-06
EA201792548A1 (ru) 2018-06-29
CO2017013229A2 (es) 2018-03-28
KR20180014422A (ko) 2018-02-08
PE20180506A1 (es) 2018-03-09
RS59220B1 (sr) 2019-10-31
IL255951A (en) 2018-01-31
CY1121938T1 (el) 2020-10-14
ES2739526T3 (es) 2020-01-31
MA41562B1 (fr) 2019-05-31
MY189453A (en) 2022-02-14
US20190263791A1 (en) 2019-08-29
EP3303330B1 (en) 2019-05-01
TN2017000503A1 (en) 2019-04-12
ME03474B (me) 2020-01-20
JP2018516928A (ja) 2018-06-28
PH12017502158A1 (en) 2018-06-11
BR112017024846A2 (pt) 2018-08-07
EP3530660A1 (en) 2019-08-28
CA2988147C (en) 2023-06-13
CN107922401A (zh) 2018-04-17
HK1247915B (zh) 2020-04-24
WO2016196771A1 (en) 2016-12-08
US20160355507A1 (en) 2016-12-08
US10336739B2 (en) 2019-07-02
JP6483288B2 (ja) 2019-03-13
JP2019094345A (ja) 2019-06-20
AR104884A1 (es) 2017-08-23
US10011594B2 (en) 2018-07-03

Similar Documents

Publication Publication Date Title
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CO2018011105A2 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2017002122A1 (es) Heterociclos bicíclicos como inhibidores de fgfr4
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
ECSP16074207A (es) Pirazinas moduladoras de gpr6
BR112016028948A2 (pt) ?composição bifásica?
CO2017007074A2 (es) Sintesis total de trioxacarcina dc-45-a2 y preparación de analogos de trioxacarcina